FDA to Bio-Makers: Tell Us About Your Oopsy-Daisies in Production
Published Date: 2/25/2026
Notice
Summary
The FDA wants to hear from companies that make biological products and human tissues about how they report mistakes during manufacturing. They’re asking for feedback on updating the forms and rules to keep things clear and safe. If you’re involved in making these products, you’ve got until April 27, 2026, to share your thoughts—no extra costs, just a chance to help improve the process!
Analyzed Economic Effects
4 provisions identified: 2 benefits, 1 costs, 1 mixed.
Mandatory 45‑Day Deviation Reporting
If you manufacture biological products, blood products, or regulated human cells and tissues, you must report product deviations using Form FDA 3486 as soon as possible but no later than 45 calendar days after learning of a reportable event. FDA estimates an average 2 hours to complete each deviation report; there are 17,818 total annual responses and a total estimated 43,246.25 annual burden hours (an increase of 13,602.95 hours and 2,383 responses based on FY2024 data).
Addendum and Partial Electronic Filing Rules
CBER offers an electronic report option and a web‑based addendum (Form FDA 3486A) for reports that may lead to a recall; FDA estimates 5% of CBER reports (about 825 annual addendum responses) and 15 minutes to complete each addendum. CDER currently does not accept electronic filings, so submissions to CDER must be made by non‑electronic methods.
Public Comment Opportunity by April 27, 2026
FDA is asking companies and stakeholders involved in biological product and HCT/P manufacturing to submit comments on the proposed information collection by April 27, 2026, via regulations.gov or by mail. The notice explains how to submit confidential information and that comments filed electronically will be posted publicly.
No Capital or O&M Costs Claimed
FDA states there are no capital costs or operating and maintenance (O&M) costs associated with this information collection for respondents. The burden estimate covers only reporting time, not equipment or other capital expenses.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-09767 — Oscar Bobo: Final Debarment Order
Oscar Bobo is officially banned for 5 years from importing any drugs into the U.S. because he repeatedly brought in mislabeled medicines that don’t follow FDA rules. He ignored the chance to defend himself, so the ban started on May 15, 2026. This means no drug imports from him for a while, but he can apply to end the ban anytime if he meets FDA’s conditions.
2026-09448 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Real Cost Campaign Outcomes Evaluation Study: Cohort 3
The FDA is asking for approval to collect info for the third group in its Real Cost Campaign, which teaches kids about the dangers of tobacco. This helps the FDA improve its anti-smoking messages and protect young people’s health. Comments on this info collection are open until June 12, 2026, with no new costs for participants.
2026-09543 — Agency Information Collection Activities; Proposed Collection; Comment Request; Postmarketing Adverse Experience Reporting
The FDA wants your thoughts on how drug companies report problems after their products hit the market. This affects drug makers and healthcare folks who keep track of side effects. They’re asking for comments by July 13, 2026, to help improve the process without adding extra costs or paperwork.
2026-09544 — Modified Risk Tobacco Product Application: Renewal Applications for VLN® King and VLN® Menthol King, Cigarette Products Submitted by 22nd Century Group Inc.
The FDA is inviting the public to comment on the renewal of special approval for two cigarette products by 22nd Century Group Inc. These products claim to lower health risks compared to regular cigarettes. If approved, the renewal keeps these products on the market with their modified risk status, affecting smokers and the tobacco industry starting May 13, 2026.
2026-09335 — Medical Devices; Immunology and Microbiology Devices; Classification of the Device To Detect and Identify Microorganism Nucleic Acids and Resistance Markers From Patients With Suspected Orthopedic Infection
Hey there! This update is all about a new medical device that helps doctors quickly find germs and their resistance traits in people who might have bone infections. It affects hospitals and labs by officially classifying this device, making it easier and faster to diagnose tough infections. The change kicks in soon, helping patients get the right treatment without delay—and it could save money by avoiding wrong meds!
2026-09368 — Enforcement Priorities for Certain New Tobacco Products Marketed Without Premarket Authorization; Guidance for Industry; Availability
The FDA is setting clear rules for certain new tobacco products like e-cigarettes and nicotine pouches that don’t have official approval yet. Companies selling these products without permission might face enforcement actions starting now, so they need to get authorized or risk penalties. This helps protect public health and keeps the market fair and safe.
Previous / Next Documents
Previous: 2026-03772 — Agency Information Collection Activities; Proposed Collection; Comment Request; Current Good Manufacturing Practice Regulations for Medicated Feeds
The FDA wants feedback on how medicated animal feed makers keep their records to make sure everything’s safe and up to date. This affects companies that produce medicated feeds, and they have until April 27, 2026, to share their thoughts. No big money changes yet, just a chance to improve how info is collected and stored.
Next: 2026-03774 — Agency Information Collection Activities; Announcement of Office of Management and Budget Approvals
The FDA just got the green light from the Office of Management and Budget to keep collecting important info from food and drug businesses. This means rules about food safety, facility registration, and tracking shipments stay in place through 2028, helping protect everyone’s health without extra costs or delays. If you’re involved in food or drug industries, keep an eye on these updates to stay on track!